📰 ReutersReutersCodex · 实盘不做把握 6/10
北京时间·🕒 发布 05:43:25时区推断·⟳ 抓取 05:44:01·⚡ 决策 08-06 15:44:22 +10h00m·82.3 天前
拜耳申请将Roundup和解案听证会后移3周，披露中仅涉及程序性延期与opt-out争议处理
本事件为和解推进流程的延后安排，核心为法院排期与opt-out处理，未披露和解金额（720亿元以上）之外的新对价条款、达成门槛变化或财务结果。
📄 原文Reuters↗ 原文
Bayer has asked a Missouri court to reschedule a hearing to evaluate the company's $7.25 billion proposed settlement of…
不做 拜耳（BAYN.DE）
本条为诉讼流程性延期披露，未带来可量化、新鲜且可持续的新增方向性增量；以“程序推进”替代交易信号，当前不形成可执行交易边界。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 本地信号库已抓到Reuters原文《Mexico investigating tourist hub for cyclospora after UK alert》，发布时间早于当前社媒/聚合转述，用作本次催化首发锚点。
- 法庭程序延后信息首次披露，重点在争取三周时间处理opt-out争议以推进和解流程。市场反应:未给出标的级即时异动说明
关键理由
- 本事件为和解推进流程的延后安排，核心为法院排期与opt-out处理，未披露和解金额（720亿元以上）之外的新对价条款、达成门槛变化或财务结果。
- 从已有文本看，新闻主要是司法日程协调，缺少可直接转化为近期交易方向的新增实质性利空/利多证据。
主要风险
- 若后续opt-out争议再次放大，和解可能继续延迟并引发短线波动，但当前阶段只能视为诉讼不确定性延伸，不构成明确可执行方向。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-05 · 影响 weakens
披露显示延期用于解决opt-out争议并保持和解推进逻辑，削弱了“直接即时催化化解诉讼重大新增利空”的说法。
检索:Bayer Roundup settlement hearing delayed three weeks opt-out process allows settlement to proceed 原文 ↗
工具调用 · 历史记录,结果未知(2 种)
- normalize_ticker · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 3,494 字
Bayer has asked a Missouri court to reschedule a hearing to evaluate the company's $7.25 billion proposed settlement of cases alleging that its popular weedkiller Roundup causes cancer.
Bayer's Monsanto unit and plaintiffs' lawyers who support the deal in a joint filing on Tuesday asked the court for a three-week delay which would push back the settlement approval hearing to September 10, rather than August 19.
The German drugmaking and crop science company is facing approximately 65,000 claims in U.S. state and federal courts from plaintiffs who say they developed non-Hodgkin lymphoma and other forms of cancer after using Roundup at home or on the job. Bayer, which acquired Roundup when it purchased Monsanto in 2018, has said that decades of studies have shown Roundup's key ingredient, glyphosate, is safe, and does not cause cancer.
Attorneys representing plaintiffs objecting to the settlement have criticized several aspects of the settlement, saying that the Missouri state court does not have the power to bind citizens of other U.S. states and that Bayer's "draconian" procedures for opting out of the settlement are designed to trap people who wish to pursue their lawsuits in court.
Bayer and the lawyers said in the filing that the additional time would help resolve requests to opt out of the class action settlement. They said they are considering requests from people who opted out of the settlement but now want back in, after a recent Supreme Court decision undercut one of the central legal claims in the Roundup cases.
Bayer's proposal aims to bring closure by resolving current and future claims that Roundup causes non-Hodgkin lymphoma, and it said when announcing the deal that the settlement won't go forward if too many people opt out. If more than 650 class members opt out, Bayer can deduct what it would have paid them from the overall settlement fund, up to $400 million.
The settlement allows Bayer and the lead class action attorneys to vet and possibly deny opt-outs, which has been criticized by lawyers for plaintiffs who oppose the settlement. Lawyers who support the deal have said that the vetting process will ensure that invalid opt-outs don't end up causing the deal to fail, but lawyers who oppose the deal say that allowing Bayer to contest the opt-outs creates a needless bureaucratic hurdle for people who don't want to join the settlement.
The three-week delay will also help resolve disputes over the validity of contested opt-out decisions, according to the joint filing.
The proposed settlement, if approved, would resolve most of the current Roundup cases in the U.S. It would not address currently pending Roundup cases that are consolidated in a federal court proceeding.
The case is King v. Monsanto, City of St. Louis Circuit Court, No. 2622-CC00325
For Bayer: Elaine Golin, Jeffrey Wintner and Carrie Reilly of Wachtell Lipton Rosen & Katz; Daniel Nelson and Derek Kraft of Gibson Dunn & Crutcher LLP; James Bennet of Dowd Bennett
Class counsel: Seeger Weiss; Motley Rice; Williams Hart & Boundas; Waters Kraus Paul & Siegel; The Holland Law Firm; Ketchmark & McCreight.
For objecting plaintiffs: Ashley Keller of Keller Postman LLC and R. Prescott Sifton of Frazer PLC.
Read more:
What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits? US Supreme Court scales back Roundup cancer suits in win for Bayer
Bayer proposes $7.25 billion plan to settle Roundup cancer cases
Bayer's Monsanto unit and plaintiffs' lawyers who support the deal in a joint filing on Tuesday asked the court for a three-week delay which would push back the settlement approval hearing to September 10, rather than August 19.
The German drugmaking and crop science company is facing approximately 65,000 claims in U.S. state and federal courts from plaintiffs who say they developed non-Hodgkin lymphoma and other forms of cancer after using Roundup at home or on the job. Bayer, which acquired Roundup when it purchased Monsanto in 2018, has said that decades of studies have shown Roundup's key ingredient, glyphosate, is safe, and does not cause cancer.
Attorneys representing plaintiffs objecting to the settlement have criticized several aspects of the settlement, saying that the Missouri state court does not have the power to bind citizens of other U.S. states and that Bayer's "draconian" procedures for opting out of the settlement are designed to trap people who wish to pursue their lawsuits in court.
Bayer and the lawyers said in the filing that the additional time would help resolve requests to opt out of the class action settlement. They said they are considering requests from people who opted out of the settlement but now want back in, after a recent Supreme Court decision undercut one of the central legal claims in the Roundup cases.
Bayer's proposal aims to bring closure by resolving current and future claims that Roundup causes non-Hodgkin lymphoma, and it said when announcing the deal that the settlement won't go forward if too many people opt out. If more than 650 class members opt out, Bayer can deduct what it would have paid them from the overall settlement fund, up to $400 million.
The settlement allows Bayer and the lead class action attorneys to vet and possibly deny opt-outs, which has been criticized by lawyers for plaintiffs who oppose the settlement. Lawyers who support the deal have said that the vetting process will ensure that invalid opt-outs don't end up causing the deal to fail, but lawyers who oppose the deal say that allowing Bayer to contest the opt-outs creates a needless bureaucratic hurdle for people who don't want to join the settlement.
The three-week delay will also help resolve disputes over the validity of contested opt-out decisions, according to the joint filing.
The proposed settlement, if approved, would resolve most of the current Roundup cases in the U.S. It would not address currently pending Roundup cases that are consolidated in a federal court proceeding.
The case is King v. Monsanto, City of St. Louis Circuit Court, No. 2622-CC00325
For Bayer: Elaine Golin, Jeffrey Wintner and Carrie Reilly of Wachtell Lipton Rosen & Katz; Daniel Nelson and Derek Kraft of Gibson Dunn & Crutcher LLP; James Bennet of Dowd Bennett
Class counsel: Seeger Weiss; Motley Rice; Williams Hart & Boundas; Waters Kraus Paul & Siegel; The Holland Law Firm; Ketchmark & McCreight.
For objecting plaintiffs: Ashley Keller of Keller Postman LLC and R. Prescott Sifton of Frazer PLC.
Read more:
What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits? US Supreme Court scales back Roundup cancer suits in win for Bayer
Bayer proposes $7.25 billion plan to settle Roundup cancer cases
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。